Epithelial ovarian cancer: Does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance?

Acta Obstetricia et Gynecologica Scandinavica

Volumn 88, Issue 4, 2009, Pages 373-377

  Larsen, Erling ^a   Blaakr, Jan ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

chemotherapy; Ovarian cancer; prognosis; surgery; time interval

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CYTOREDUCTIVE SURGERY; EXPERIMENTAL STUDY; HUMAN; OVARY CANCER; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; TIME; FEMALE; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM; OVARY TUMOR; POSTOPERATIVE PERIOD; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POSTOPERATIVE PERIOD; PROGNOSIS; SURVIVAL RATE; TIME FACTORS;

EID: 64849086564     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340902814559     Document Type: Article

References (8)

1. Sorbe B. Prognostic importance of the time interval from surgery to chemotherapy in treatment of ovarian carcinoma. Int J Gynecol Cancer. 2004;14:788-93.
2. Flynn P, Paul J, Cruickshank DJ. Does the interval from primary surgery to chemotherapy influence progression -free survival in ovarian cancer? Gynecol Oncol. 2002;86: 354-7.
3. Paulsen T, Kærn J, Kjærheim K, Haldorsen T, Tropé C. Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer. Gynecol Oncol. 2006;102:447-52.
4. Gadduci A, Sartori E, Landoni F, Zola P, Maggino T, Maggioni A, et al. Relationship between interval from primary surgery to the start of taxane- plus platinum- based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study. J Clin Oncol. 2005;23:751-8.
5. Rosa DD, Clamp A, Mullamitha S, Ton NC, Lau S, Byrd L, et al. The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Eur J Surg Oncol. 2006;32:588-91.
6. Aletti GD, Long HJ, Podratz KC, Cliby WA. Is time to chemotherapy a determinant of prognosis in advanced stage ovarian cancer? Gynecol Oncol. 2007;104:212-6.
7. Wright JD, Doan T, McBride R, Jacobson JS, Hershman DL. Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. Br J Cancer. 2008;98:1197-203.
8. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumour removal and chemotherapy on kinetics and growth of metastases. Cancer Res. 1983;43: 1488-92. 9. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumour. Cancer Res. 1979; 39:3861-5. 10. Schiffenbauer YS, Abramavitch R, Meir G, Nevo N, Holzinger M, Itin A, et al. Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc Natl Acad Sci. 1997;94:13203-8. 11. Kiguchi K, Kubota T, Aoki D, Udagawa Y, Yamanouchi S, Saga M, et al. A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer. Clin Exp Metastasis. 1998;16:751-6.